JP2020513016A - 能力と安全性が増強された組成物および抗菌合成カチオン性ポリペプチド類を局所的に適用する使用 - Google Patents

能力と安全性が増強された組成物および抗菌合成カチオン性ポリペプチド類を局所的に適用する使用 Download PDF

Info

Publication number
JP2020513016A
JP2020513016A JP2019554855A JP2019554855A JP2020513016A JP 2020513016 A JP2020513016 A JP 2020513016A JP 2019554855 A JP2019554855 A JP 2019554855A JP 2019554855 A JP2019554855 A JP 2019554855A JP 2020513016 A JP2020513016 A JP 2020513016A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antimicrobial
synthetic cationic
antibacterial
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019554855A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020513016A5 (https=
Inventor
ピー． ベヴィラックア，マイケル
ピー． ベヴィラックア，マイケル
ジェイ． ファン，ダニエル
ジェイ． ファン，ダニエル
ルーカー，ダグ
Original Assignee
アミクローブ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アミクローブ，インコーポレイテッド filed Critical アミクローブ，インコーポレイテッド
Publication of JP2020513016A publication Critical patent/JP2020513016A/ja
Publication of JP2020513016A5 publication Critical patent/JP2020513016A5/ja
Priority to JP2023028902A priority Critical patent/JP7656643B2/ja
Priority to JP2025049135A priority patent/JP2025090864A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028—Polypeptides; Proteins; Degradation products thereof
    • A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Materials Engineering (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)
JP2019554855A 2017-04-06 2018-04-05 能力と安全性が増強された組成物および抗菌合成カチオン性ポリペプチド類を局所的に適用する使用 Pending JP2020513016A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023028902A JP7656643B2 (ja) 2017-04-06 2023-02-27 能力と安全性が増強された組成物および抗菌合成カチオン性ポリペプチド類を局所的に適用する使用
JP2025049135A JP2025090864A (ja) 2017-04-06 2025-03-24 能力と安全性が増強された組成物および抗菌合成カチオン性ポリペプチド類を局所的に適用する使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762482630P 2017-04-06 2017-04-06
US62/482,630 2017-04-06
PCT/US2018/026322 WO2018187617A1 (en) 2017-04-06 2018-04-05 Compositions and uses of locally applied antimicrobials with enhanced performance and safety

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023028902A Division JP7656643B2 (ja) 2017-04-06 2023-02-27 能力と安全性が増強された組成物および抗菌合成カチオン性ポリペプチド類を局所的に適用する使用

Publications (2)

Publication Number Publication Date
JP2020513016A true JP2020513016A (ja) 2020-04-30
JP2020513016A5 JP2020513016A5 (https=) 2021-05-06

Family

ID=63712780

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019554855A Pending JP2020513016A (ja) 2017-04-06 2018-04-05 能力と安全性が増強された組成物および抗菌合成カチオン性ポリペプチド類を局所的に適用する使用
JP2023028902A Active JP7656643B2 (ja) 2017-04-06 2023-02-27 能力と安全性が増強された組成物および抗菌合成カチオン性ポリペプチド類を局所的に適用する使用
JP2025049135A Pending JP2025090864A (ja) 2017-04-06 2025-03-24 能力と安全性が増強された組成物および抗菌合成カチオン性ポリペプチド類を局所的に適用する使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023028902A Active JP7656643B2 (ja) 2017-04-06 2023-02-27 能力と安全性が増強された組成物および抗菌合成カチオン性ポリペプチド類を局所的に適用する使用
JP2025049135A Pending JP2025090864A (ja) 2017-04-06 2025-03-24 能力と安全性が増強された組成物および抗菌合成カチオン性ポリペプチド類を局所的に適用する使用

Country Status (11)

Country Link
US (3) US11285189B2 (https=)
EP (1) EP3606543A4 (https=)
JP (3) JP2020513016A (https=)
KR (2) KR20200018400A (https=)
CN (1) CN110740744A (https=)
AU (2) AU2018249552A1 (https=)
BR (1) BR112019020781A2 (https=)
CA (1) CA3058901C (https=)
MX (2) MX393548B (https=)
SG (1) SG11201909016TA (https=)
WO (1) WO2018187617A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2991989T3 (es) 2012-03-23 2024-12-05 Macro Biologics Inc Composiciones y usos de materiales antimicrobianos con propiedades compatibles con tejidos
US11285189B2 (en) 2017-04-06 2022-03-29 Amicrobe, Inc. Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety
JP2023501385A (ja) 2019-11-08 2023-01-18 ユニバーシティ オブ ピッツバーグ － オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 抗微生物ペプチドを含む組成物
WO2021202577A1 (en) * 2020-03-31 2021-10-07 3-D Matrix, Ltd. Sterilization of self-assembling peptides by irradiation
US20230149333A1 (en) * 2020-04-08 2023-05-18 Amicrobe, Inc. Compositions and uses of locally applied synthetic amino acid polymers for prevention and treatment of viral infections
US12371463B2 (en) 2021-04-20 2025-07-29 University of Pittsburgh—of the Commonwealth System of Higher Education Methods and compositions for treatment of antibiotic-resistant bacterial infections

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012041367A (ja) * 2001-08-21 2012-03-01 Carrus Capital Corp 抗菌性カチオン性ペプチドおよびそれらの処方物
JP2013536242A (ja) * 2010-08-23 2013-09-19 ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア 高抗微生物活性および低毒性を有する材料の組成物および使用
JP2015512403A (ja) * 2012-03-23 2015-04-27 アミクローブ，インコーポレイテッド 組織適合特性を有する抗菌剤の組成物および使用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5636643A (en) 1991-11-14 1997-06-10 Wake Forest University Wound treatment employing reduced pressure
US6686446B2 (en) 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6632922B1 (en) 1998-03-19 2003-10-14 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6680365B1 (en) 1998-03-19 2004-01-20 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
TW570805B (en) 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
US8206749B1 (en) 1999-02-26 2012-06-26 Novartis Vaccines And Diagnostics, Inc. Microemulsions with adsorbed macromolecules and microparticles
MXPA03002640A (es) 2000-09-28 2003-06-19 Chiron Corp Microparticulas para la distribucion de acidos nucleicos heterologos.
US6818732B2 (en) 2001-08-30 2004-11-16 The Regents Of The University Of California Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers
JP2003171463A (ja) * 2001-12-06 2003-06-20 Chisso Corp ポリリジン及びその製造法
CA2443472A1 (en) 2002-02-07 2003-08-14 Ophtecs Corporation Liquid formulation for contact lenses
CN103405405A (zh) 2002-12-09 2013-11-27 阿布拉西斯生物科学有限责任公司 组合物和传递药剂的方法
EP1644382B1 (en) 2003-07-11 2008-03-05 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
WO2005018701A1 (en) 2003-08-25 2005-03-03 Kane Biotech Inc. Synergistic antimicrobial compositions and methods of inhibiting biofilm formation
WO2005063278A1 (en) 2003-12-30 2005-07-14 Bioactive Polymers Ab Surface protection of exposed biological tissues
ATE381945T1 (de) * 2004-03-12 2008-01-15 Intercell Ag Verfahren zur solubilisierung von peptid- mischungen
PL1778720T3 (pl) 2004-08-18 2011-03-31 Novabiotics Ltd Antybakteryjne peptydy zawierające wzór zawierający argininę i/lub lizynę
EP1891097B1 (en) 2005-06-06 2016-11-16 Adenium Biotech ApS Polypeptides having antimicrobial activity and polynucleotides encoding same
US20080139450A1 (en) 2005-07-01 2008-06-12 Srinivasa Madhyastha Antimicrobial Compositions and Uses Thereof
US20070190110A1 (en) 2006-02-10 2007-08-16 Pameijer Cornelis H Agents and devices for providing blood clotting functions to wounds
CA2671461C (en) 2006-12-01 2014-01-28 The Regents Of The University Of California Vesicles of self-assembling block copolymers and methods for making and using the same
CN101720237A (zh) 2007-06-25 2010-06-02 利波佩普蒂德有限公司 新型医用产品
WO2009032605A2 (en) 2007-08-27 2009-03-12 Massachusetts Institute Of Technology Bi-functional polymer-attached inhibitors of influenza virus
KR20110031168A (ko) 2008-06-19 2011-03-24 니뽄 신야쿠 가부시키가이샤 약물 담체
CN102256613B (zh) 2008-10-20 2014-09-10 莫伊莱麦屈克斯公司 用于治疗或者预防粘连的多肽
WO2010083589A1 (en) 2009-01-23 2010-07-29 Kane Biotech Inc. Biofilm-removing antimicrobial compositions and uses thereof
GB0905451D0 (en) 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
SG184836A1 (en) 2010-04-27 2012-11-29 Lysando Ag Method of reducing biofilms
JP5613779B2 (ja) * 2011-01-19 2014-10-29 株式会社メニコン コンタクトレンズ用液剤
US9781949B2 (en) 2011-03-31 2017-10-10 The University Of Massachusetts Antimicrobial delivery systems, methods of manufacture, and methods of use thereof
DE102014101663A1 (de) 2014-02-11 2015-08-13 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Synthetische artifizielle Peptide mit antimikrobieller Wirkung
WO2016044683A1 (en) 2014-09-19 2016-03-24 Tensive Controls, Inc. Anti-microbial peptides
EP3215126A1 (en) 2014-10-30 2017-09-13 Biomet Manufacturing, LLC Methods of preventing surgical site infections
JP2016113373A (ja) * 2014-12-11 2016-06-23 エスポ化学株式会社 抗菌性、抗ウイルス性を有する水溶性組成物
US11285189B2 (en) 2017-04-06 2022-03-29 Amicrobe, Inc. Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety
US20210007999A1 (en) 2018-03-02 2021-01-14 January Therapeutics, Inc. Nanoparticle compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012041367A (ja) * 2001-08-21 2012-03-01 Carrus Capital Corp 抗菌性カチオン性ペプチドおよびそれらの処方物
JP2013536242A (ja) * 2010-08-23 2013-09-19 ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア 高抗微生物活性および低毒性を有する材料の組成物および使用
JP2015512403A (ja) * 2012-03-23 2015-04-27 アミクローブ，インコーポレイテッド 組織適合特性を有する抗菌剤の組成物および使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MACROMOL. BIOSCI. (MAR 2017) VOL.17,ISSUE 10, 1600492, JPN6021051675, ISSN: 0004904168 *

Also Published As

Publication number Publication date
KR20240135875A (ko) 2024-09-12
JP7656643B2 (ja) 2025-04-03
MX393548B (es) 2025-03-24
CN110740744A (zh) 2020-01-31
WO2018187617A8 (en) 2019-10-17
CA3058901C (en) 2025-05-06
WO2018187617A1 (en) 2018-10-11
EP3606543A1 (en) 2020-02-12
AU2023202283A1 (en) 2023-05-11
CA3058901A1 (en) 2018-10-11
JP2023054375A (ja) 2023-04-13
KR20200018400A (ko) 2020-02-19
JP2025090864A (ja) 2025-06-17
US11285189B2 (en) 2022-03-29
RU2019133628A3 (https=) 2021-07-14
US12268722B2 (en) 2025-04-08
EP3606543A4 (en) 2020-12-16
RU2019133628A (ru) 2021-05-06
US20210100867A1 (en) 2021-04-08
US20260041728A1 (en) 2026-02-12
AU2018249552A1 (en) 2019-10-31
US20230017994A1 (en) 2023-01-19
SG11201909016TA (en) 2019-10-30
BR112019020781A2 (pt) 2020-04-28
MX2022007904A (es) 2022-07-21

Similar Documents

Publication Publication Date Title
JP7656643B2 (ja) 能力と安全性が増強された組成物および抗菌合成カチオン性ポリペプチド類を局所的に適用する使用
Zhang et al. An injectable dipeptide–fullerene supramolecular hydrogel for photodynamic antibacterial therapy
KR102266659B1 (ko) 조직-적합성 특성을 갖는 항균물질의 조성물 및 용도
JP2010506974A (ja) インサイツで形成されるヒドロゲル創傷包帯および生体適合材料ならびにそれらの使用
MXPA04010325A (es) Biomateriales novedosos, su preparacion y uso.
JP2012523449A (ja) スルファジアジン銀およびキトサンを使用して製造された薬用クリーム剤ならびにそれを製造する方法
Das et al. The gamut of perspectives, challenges, and recent trends for in situ hydrogels: A smart ophthalmic drug delivery vehicle
WO2023019143A1 (en) Films formed from self-assembling peptide hydrogels
JP2005529906A (ja) キサンタンガムを含む再上皮化医薬組成物
EP4192491A2 (en) Antimicrobial matrix formed from peptide hydrogels
CN109568645B (zh) 一种复合生长因子促修复凝胶及其制备方法与应用
EP4100029A1 (en) Compositions and methods of use thereof for treatment of mastitis
RU2824578C2 (ru) Композиции и применения антимикробных средств для местного применения с улучшенными характеристиками и безопасностью
WO2021169075A1 (zh) 一种集可注射与抗菌于一体的双功能水凝胶及其制备方法和用途
Mao et al. A review on in situ gels as polymer drug carriers in the treatment of periodontitis
WO2022035784A1 (en) Antifungal matrix formed from peptide hydrogels
JP2002511493A (ja) 低溶解度抗生物質による細菌耐性の破壊
EP4356929A1 (en) Antifibrotic formulation for ophthalmic treatment
WO2026060306A1 (en) Compositions and uses of locally applied synthetic cationic and hydrophobic amino acid block copolymers, for prevention and treatment of bacterial and fungal infections
US20230149333A1 (en) Compositions and uses of locally applied synthetic amino acid polymers for prevention and treatment of viral infections
CN117598991A (zh) 一种抗皮肤创伤多重耐药菌mrsa感染的纳米乳消毒剂制备方法及其应用
CN113041340A (zh) 一种生物杀菌凝胶及其制备方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210323

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220705

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221025